The company’s lead candidate is against human cytomegalovirus, with clinical studies planned for 2022 and the company sees a range of development opportunities in infectious diseases and beyond.

In 2020, SpyBiotech signed an exclusive global licensing agreement with the Serum Institute of India for the development of a novel virus-like-particle vaccine targeting COVID-19.